EXPRESS MAIL NOS, EM245163097US AND EM245163106US

Substitute for form 1449/PTO INFORMATION DISCLOSURE

OIFE

AUG 2 7 7008 THADEN

> Sheet 1 1

STATEMENT BY APPLICANT (Use as many sheets as necessary)

> of 17

Complete if Known Application Number 09/506,079 Filing Date February 16, 2000 First Named Inventor Gail M. Clinton Art I Init 1643 Examiner Name Anne L. Holleran Attorney Docket Number 49321-16

Examiner nitials*	Cite No. 1	Document Number Number-Kind Code ¹ (if known)	Publication Date MM-DD-YYYY	Name of Pater Applicant of Cited	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/A.H./		US-4,376,110	03-08-1983	David et al.	
		US-4,777,127	10-11-1988	Suni et al.	
		US-4,946,778	08-07-1990	Ladner et al.	
		US-4,959,314	09-25-1990	Mark et al.	
-		US-5,149,655	09-22-1992	McCabe et al.	
		US-5,206,152	04-27-1993	Sukhatme	
		US-5,219,740	06-15-1993	Miller et al.	
		US-5,422,120	06-06-1995	Kim	
		US-5,580,859	12-03-1996	Felgner et al.	
		US-5,705,157	01-06-1998	Greene et al.	
		US-5,720,954	02-24-1998	Hudziak et al.	
		US-5,772,997	06-30-1998	Hudziak et al.	
		US-5,811,098	09-22-1998	Plowman et al	
		US-5,814,482	09-29-1998	Dubensky, Jr. et al.	
		US-5,876,712	03-02-1999	Cheever et al.	
		US-6,331,526	12-18-2001	Baserga et al.	
		US-6,337,338	01-08-2002	Kozlowski et al.	
		US-6,340,674	01-22-2002	Baserga et al.	
		US-6,541,214	04-01-2003	Clinton	
		US-6,673,343	01-06-2004	Bennett et al.	
		US-6,841,367	01-11-2005	Kendall et al.	
		US-7,125,680	10-24-2006	Singer et al.	
		US-2002/0064785	05-30-2002	Mass	
		US-2002/0173458	11-21-2002	Ruben et al.	
		US-2003/0059863	03-27-2003	Clinton	
		US-2003/0105051	06-05-2003	McSwiggen	
		US-2003/0157097	08-21-2003	Noguchi et al.	
V_		US-2003/0171278	09-11-2003	Dennis	

EXAMINER; Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation Examination. Inside the design of the properties a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to resp

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) of

Sheet ١,

Complete if Known				
Application Number	09/506,079			
Filing Date	February 16, 2000			
First Named Inventor	Gail M. Clinton			
Art Unit	1643			
Examiner Name	Anne L. Holleran			
Attorney Docket Number	49321-16			

Examiner	Cite		Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant
nitials*	No.1	Document Number	MM-DD-YYYY	Applicant of Cited Document	Figures Appear
/A.H./		US-2003/0228663	12-11-2003	Lowman et al.	
		US-2003/0235556	12-25-2003	Wolin et al.	
		US-2004/0022785	02-05-2004	Clinton et al.	
		US-2004/0023887	02-05-2004	Pillutla et al.	
		US-2004/0052796	03-18-2004	Clinton	
		US-2004/0082510	04-29-2004	Ulirich et al.	
		US-2004/0106161	06-03-2004	Bossenmaier et al.	
		US-2004/0142931	07-22-2004	Vite et al.	
٠, ١,		US-2004/0242684	12-02-2004	Chen et al.	
V		US-2005/0239088	10-27-2005	Shepard et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
/A.H./		AU 777422	10-14-2004	Oregon Health Sciences University		
		AU 777803	10-28-2004	Oregon Health Sciences University		
		CA 2,418,083	02-14-2002	Imclone Systems, Inc.		
		CN 1607247	04-20-2005	Shanghai Haixin Bio Tech Co Lt (CN)		
		EP 0345242	12-06-1989	SmithKline Biolog (BE)		
		EP 0524968	02-03-1993	Research Development Foundation		
		GB 2200651	08-10-1988	Al Sumidale Ayad Mohamed Khala		
		WO 90/07936	07-26-1990	Chiron Corporation		
		WO 90/11092	10-04-1990	Vical, Inc.		
		WO 91/02805	03-07-1991	Viagene, Inc.		
$\bot V$		WO 91/11715	08-08-1991	State of Oregon		

Examiner	/Anne Holleran/	Date	09/06/2008
Signature		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation Examen. Immel interests considered, wherein unit ordation is in continuation on where Fog. Draw line through clatton i not in conformation and not considered include copy of this form with next communication to applicant. *Applicant is unique citation designation number (policion). *See Kinds Codes of USPTO Patent Documents at www.usdn.gov or MFEP 90.104. *Enter Office that issued the document, by the volument code (MFD Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449/PTO

Shoot 1 3

(Use as many sheets as necessary) of

17

Complete if Known			
Application Number	09/506,079		
Filing Date	February 16, 2000		
First Named Inventor	Gail M. Clinton		
Art Unit	1643		
Examiner Name	Anne L. Holleran		
Attorney Docket Number	49321-16		

			FOREIGN PATENT DOCU			
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	т
/A.H./		WO 91/14445	10-03-1991	Research Development Foundation		
		WO 92/11033	07-09-1992	Arch Development Corporation		
		WO 93/03769	03-04-1993	The United States of America		
		WO 93/10218	05-27-1993	The United States Government		
		WO 93/11230	06-10-1993	Dynal AS		
T		WO 93/14778	08-05-1993	Vical, Inc.		
		WO 93/19191	09-30-1993	Centre National de la Recherche Scientifique		
		WO 93/25234	12-23-1993	The Regents of the University of California		
		WO 93/25698	12-23-1993	The United States Government		
		WO 94/03622	02-17-1994	Imperial College of Science		
		WO 94/12649	06-09-1994	Genzyme Corporation		_
		WO 94/23697	10-27-1994	Depotech Corporation		_
		WO 94/28938	12-22-1994	The Regents of the University of Michigan		
		WO 95/00655	01-05-1995	Mc Master University		
		WO 95/07994	03-23-1995	Viagene, Inc.	ļ	_
		WO 95/11984	05-04-1995	Canji, Inc.		╙
		WO 95/13796	05-26-1995	Depotech Corporation		_
		WO 95/30763	11-16-1995	Viagene, Inc.		_
		WO 96/17072	06-06-1996	Chiron Viagene, Inc.		_
		WO 97/18241	05-22-1997	Thomas Jefferson University		L
		WO 97/42338	11-13-1997	Chiron Corporation		Ш
Ψ		WO 00/29609	05-25-2000	Oregon Health Sciences University		

Examiner	/Anne Holleran/	Date	
Signature		Considered	09/06/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation EXAMENCE. Install interested considered, welcare or not caston is in conformation with which 2009. Unaw line through classon in not conformation and not considered. Include copy of this form with net communication to applicant. Applicant is unique classion designation number (points). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the No-letter code (WIPO Startard ST 3). "For Japanese patent cocuments, the indication of the year of the reight of the Emporor must precede the sarial number of the patent document." Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. "Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Tademark Reduction Act of 1995, no persons ere required to respond to as obtained under site with the Paperwork Reduction Act of 1995, no persons ere required to respond to a collection of information unfe

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449/PTO

Sheet

(Use as many sheets as necessary) of

Complete if Known			
Application Number	09/506,079		
Filing Date	February 16, 2000		
First Named Inventor	Gail M. Clinton		
Art Unit	1643		
Examiner Name	Anne L. Holleran		
Attorney Docket Number	49321-16		

			FOREIGN PATENT DOCL	MENIS		_
Examiner nitials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documer	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	١,
/A.H./		WO 00/35455	08-22-2000	Telik, Inc.		Г
		WO 00/44403	08-03-2000	Oregon Health Sciences University		
		WO 01/61356	08-23-2001	Oregon Health Sciences University		
		WO 02/12335	02-14-2002	Pharmacia Corporation		
T		WO 02/14470	02-21-2002	Oregon Health and Scient University	æ	
		WO 03/061571	07-31-2003	Chiron Corporation		
		WO 03/070747	08-28-2003	Novo Nordisk		
		WO 2004/041065	05-21-2004	The United States of America		
		WO 2004/054996	07-01-2004	Axelar AB		L
		WO 2004/055022	07-01-2004	Axelar AB		
		WO 2005/016966	02-24-2005	Receptor BioLogix, Inc.		
		WO 2005/112969	12-01-2005	Oregon Health and Scien University	ce .	
$\overline{\mathbf{V}}$		WO 2006/042002	04-20-2006	Oregon Health and Scien University	De l	Γ
		NO	N PATENT LITERATURE	DOCUMENTS		
	T	Include name of the author (in CAPIT	ALL ETTERS) title of the artic	te (when annonviste) title of t	ne item (book manazine journal	
Examiner Initials*	Cite No.	, se	nal, symposium, catalog, etc.), number(s), publisher, city and/o	date, page(s), volume-issue	to norm (book, magazino, journal,	T
7A.H./		ADACHI et al., "Effects of Genetic Lines," Gastroenterology 123(4):1	: Blockage of the Insulin-like 191-1204, October 2002	Growth Factor Receptor in	Human Colon Cancer Cell	
		AHMAD, et al., "The Mitogenic Ac Requires the Epidermal Growth F January 16, 2004	tion of Insulin-like Growth Fa actor Receptor Tyrosine Kin	actor I in Normal Human Ma ase," Journal of Biological C	nmary Epithelial Cells hemistry 297(3):1713-1719,	
		ALBANELL et al., "Mechanism of 2C4," New Trends in Cancer for t	Action of Anti-HER2 Monocl he 21 st Century, Kluwer Aca	onal Antibodies: Scientific U demic/Plenum Publishers, N	pdate on Trastuzumab and ew York, pp. 253-268, 2003	
		ANDREWS et al., "Results of a Pi the Insulin-Like Growth Factor Ty 2200, April 15, 2001	ilot Study Involving the Use of pe I Receptor in Malignant A	of an Antisense Oligodeoxyr strocytomas," Journal of Cli	ucleotide Directed Against rical Oncology 19(8):2189-	
Examiner Signature	Т	/Anne Holleran/		Date	09/06/2008	

Signature Considered EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation

Examination in reterence consolvents, whereing or not cision is in contornation with network of the foreign classo in not in conformation and not considered. Include copy of his form with net communication to applicant. * *poplicant** unique cision designation number (policions)* See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 *Enter Office that issued the document, by the No-letter code (WPD Standard ST.3). *For Japanese patent documents, be indication of the year of the neight of the Emperor must proceed the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.3. 16 if possible. *Applicant is to place the patent of the patent o a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gethering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TOSSUESA (08-00)

APPOPER for use through (731,000) MB (08-00)

U.S. Palent and Trademark (filter, U.S. DEPARTIMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless (inclusins a valid offer for untrade).

INFORMATIO	N DISCL	OSURE
STATEMENT	BY APPL	ICANT

Substitute for form 1449/PTO

Sheet 5

Signature

(Use as many sheets as necessary) of

17

Complete if Known			
Application Number	09/506,079		
Filing Date	February 16, 2000		
First Named Inventor	Gail M. Clinton		
Art Unit	1643		
Examiner Name	Anne L. Holleran		
Attorney Docket Number	49321-16		

	,	NON PATENT LITERATURE DOCUMEN	rs		_
aminer tials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appn serial, symposium, catalog, etc.), date, page(s) number(s), publisher, city and/or country whe	volume-issue	e item (book, magazine, journal,	т
4.H./		ARIHIRO et al., "Expression of CD31, Met/hepatocyte growth factor recept metastasis of osteosarcoma," Pathology International 51:100-106, 2001	r and bone mor	phogenetic protein in bone	
		AZUMA et al., "Identification of HER2/neu-derived peptides capable of induresponses in HLA-A24 positive breast cancer patients," Breast Cancer Res			
		BAASNER et al., "Reversible tumorigenesis in mice by conditional express kinase," Oncogene 13(5):901-11, 1996	on of the HER2/	c-erbB2 receptor tyrosine	
		BARGMAN et al., "Oncogenic activation of the neu-encoded receptor prote Journal 7(7):2043-2052, 1988	n by point muta	tion and deletion," EMBO	
		BASELGA et al., "Phase II Study of Weekly Intravenous Recombinant Hum Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Ca 14(3):737-744, 1996	enized Anti-p18 cer,* Journal of	5(HER2) Monoclonal Clinical Oncology	
<u> </u>		BASERGA, "Haystacks and Needles," Human Pathology 31(3):275-276, M	rch 2000		
		BASU et al., "Inhibition of tyrosine kinase activity of the epidermal growth from that binds to EGF: role for interreceptor interaction in kinase regulation			
		BAZLEY et al., "The epidermal growth factor receptor family," Endocrine-R	lated Cancer 1:	2:S17-S27, 2005	
		BEECH et al., "Insulin-like growth factor-I receptor antagonism results in indoxorubicin and taxol," Oncology Reports 8(2):325-329, March-April 2001	reased cytotoxi	city of breast cancer cells to	
		BENINI et al., "Inhibition of Insulin-like Growth Factor I Receptor Increases Vinoristine against Ewing's Sarcoma Cells," Clinical Cancer Research 7(6)	he Antitumor A 1790-1797, Jun	ctivity of Doxorubicin and e 2001	
		BIRD, "Single-Chain Antigen-Binding Proteins," Science 242:423-426, 198			
		BLUME-JENSEN et al., "Oncogenic kinase signalling," Nature 411(6835):3	5-365, May 17,	2001	
Τ		BOHULA et al., "Targeting the type 1 insulin-like growth factor receptor as 14(9):669-682, October 2003	nti-cancer treat	ment,* Anticancer Drugs	
		BOND et al., "Cloning and functional expression of the cDNA encoding an expressed in pancreatic beta-cells and in the brain," FEBS Letters 367:61-	nwardly-rectifyin 8, 1995	g potassium channel	
		BORK, "Powers and pitfalls in sequence analysis: the 70% hurdle," Genom	Research 10:3	398-400, 2000	
		BRANDON et al., "Estrogen Receptor Gene Expression in Human Uterine 80(6):1876-1881, 1995	eiomyomata," .	I. Clin. Endocrinol. Metab.	
		BRANDON et al., "Progesterone receptor messenger ribonucleic acid and leiomyomas," American Journal of Obstetrics and Gynecology 189(1):78-8:		expressed in human uterine	
		BRODOWICZ et al., "Soluble HER-2/neu Neutralizes Biologic Effects of An Cells in Vitro," Int. J. Cancer 73:875-879, 1997	i-HER-2/neu Ar	ntibody on Breast Cancer	
Ψ^-		BROWN et al., "Antibodies against Highly Conserved Sites in the Epiderms Domain as Probes for Structure and Function," Biochemistry 32:4659-4664		Receptor Tyrosine Kinase	
caminer	/Δ	nne Holleran/	Date	09/06/2008	

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (options)' See Kinds Codes of USPTO Patent Documents at <u>www.uspto.org</u> or MPEP 901 of 2" Either Office this issued the documents, by the two-letter code (VMPO Standard ST.3). "For Japanese patent documents, the indication of the year of the regnor of the Emperor must precade the sensi number of the patent document." Yell of document to Well of possible. "Applicant is to piece." a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB08A (08-03)
Approved for use through 07/31/0808 (08-03)
U.S. Pelent and Trainfacture. Office; U.S. EPRATMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless to contains a valid other foundation. A

F

F A

E

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449/PTO

Sheet l s

(Use as many sheets as necessary) of

17

Complete if Known		
pplication Number	09/506,079	
iling Date	February 16, 2000	
irst Named Inventor	Gail M. Clinton	
rt Unit	1643	
xaminer Name	Anne L. Holleran	
Hospey Docket Number	40221 16	

		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal,	
xaminer iitials*	Cite No. 1	include name of the author (in CAPTIALLE ITEM), tiled or the ancide (when appropriate), use of the tem (cook, magazine, journal, serial, symposium, catalog, etc.), date, pagle(s), volume-issue number(s), publisher, city and/or country where published.	T²
'A.H./		BURTRUM et al., "A Fully Human Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor Blocks Ligand- Dependent Signaling and Inhibits Human Tumor Growth in Vivo," Cancer Research 63(24):8912-8921, December 15, 2003	
		BYRON et al., "Potential Therapeutic Strategies to Interrupt Insulin-Like Growth Factor Signaling in Breast Cancer," Seminars in Oncology 30(5 Suppl 16) 125-132, October 2003	
		CAMIRAND et al., "Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells," Med Sci Monit 8(12):BR521-526, December 2002	
		CAMIRAND et al., "Co-targeting IGF-IR and c-t-it: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells," British Journal of Cancer 90(9):1825-1829, May 4, 2004	
		CAMP et al., "Molecular Mechanims of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor," Clinical Cancer Research 11(1):397-405, January 1, 2005	
		CAMPIGLIO et al., "Inhibition of Proliferation and Induction of Apoptosis in Breast Cancer Cells by the Epidermal Growth Factor Receptor (EGFR) Tyosine Kinase Inhibitor ZD 1839 (Tressa) is Independent of EGFR Expression Level, "Journal of Cellular Phisiology 198(2):289-286, February 2004	
		CARRAWAY et al., "A Neu Acquaintance for ErbB3 and ErbB4: A Role for Receptor Heterodimerization in Growth Signaling," Cell 78:(5-8), 1994	
		CARTER et al., "Tissue-Specific Transformation by Oncogenic Mutants of Epidermal Growth Factor Receptor," Critical Review in Oncogenesis 5(4):389-428, 1994	
		CHAKRAVARTI et al., "Insulin-like Growth Factor Receptor I Mediates Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Primary Human Glioblastoma Cells through Continued Activation of Phosphoinostide 3-Kinase Signalign", Cancer Research (2017) 200-2007, January 1, 2002	
		CHANG, "Enhanced Efficacy of DNA Vaccination Against Her-2/neu Tumor Antigen by Genetic Adjuvants," International Journal of Cancer 111(1):86-95, August 10, 2004	
		CHIU et al., "Tumor-largeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin®) conjugated polyethylenimine," Journal of Controlled Release 97(2):357-369, June 18, 2004	
		CHRISTIANSEN et al., "Biological impediments to monoclonal antibody-based cancer immunotherapy," Molecular Cancer Therapeutics 3(11):1493-1501, November 2004	
		CLELAND et al., "The Development of Stable Protein Formulations: A Close Look at Protein Aggregation, Deamidation, and Oxidation," Critical Reviews in Therapeutic Drug Carrier Systems 10(4):307-377, 1993	
		CLINTON et al., "Estrogen action in human ovarian cancer," Crit. Rev. Oncol/Hematol. 25:1-9, 1997	
		CLINTON et al., "Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells," Proc. Natl. Acad. Sci. 93:316-320, 1996	
Ψ^{-}		CLINTON et al., "Generation and Use of Anti-peptide Antibodies Directed against Catalytic Domain of Protein Kinases," Methods in Enzymology 200.483-474, 1991	

Examiner	/Anne Holleran/	Date 09/06/2008	٦
Signature		Considered	- 1

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation Examine... Imitial in returning considered, whether or not ciption is in conformation with MPEP 699. Draw line through citation if no conformation and not considered. Include copy of this form with next communication to applicant. *\ \text{Application} \text{ in significant consists} \text{ in conformation} \text{ in a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 tall of the CSP to process, an application, commissionally is governed by a CSP, and a CSP to process, an application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Complete if Known

09/506,079

49321-16

February 16, 2000

Approved for use through 07/31/2006. OMB 0853-0431

U.S. Patient and Trademan (Office; U.S. DE PARTNEET OF COMMERCE
Under the Papermon's Reduction Act of 1995, no persons are required to respond to a collection of Information unless it commands as valid Office control number.

Attorney Docket Number

Substitute for form 144a/ 10	
INFORMATION DISCLOSURE	Application Number
	Filing Date
	First Named Invento

of 1 17

Sheet 7

st Named Inventor Gail M. Clinton (Use as many sheets as necessary) Art Unit 1643 Examiner Name Anne L. Holleran

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. '	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pageds), volume-issue number(s), publisher, diy and/or country where polished.	T ²
/A.H./		CODONY-SERVAT et al., "Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the lissue inhibitor of metalloproteases-1 in breast cancer cells," Cancer Res. 59(6):1196-1201, 1999	
		COLE et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer," Monoclonal Antibodies and Cancer Therapy," Alan R. Liss, Inc., pp. 77-96, 1985	
		CONNELLY et al., "In Vivo Gene Delivery and Expression of Physiological Levels of Functional Human Factor VIII in Mice," Human Gene Therapy 6(2):185-193, February 1995	
		COTE et al., "Generation of human monoclonal antibodies reactive with cellular antigens," Proc. Natl. Acad. Sci. 80:2026-2030, 1983	
		CUNNINGHAM et al., "High-Resolution Epitope Mapping of NGH-Receptor Interactions by Alanine-Scanning Mutagenesis," Science 244(4908):1081-1085, June 2, 1989	
		CURIEL et al., "High-Efficiency Gene Transfer Mediated by Adenovirus Coupled to DNA-Polylysine Complexes," Human Gene Therapy 3(2):147-154, April 1992	
	Ι	CURTI, "Physical barriers to drug delivery in tumors," Critical Reviews in Oncology/Hematology 14:29-39, 1993	
		DATABASE, Database accession No. P04626, ERB2_HUMAN, "Receptor tyrosine-protein kinase erb8-2 precursor," created 8/13/87, www.ebi.uniprot.org/uniprot-sn/juniProtView.do?proteinID=ERB2_HUMAN&pager.diset=nult	
		DATTA et al., "Cellular survival: a play in three Akts," Genes & Development 13:2905-2927, November 1999	
		DE GIOVANNI et al., "Immunoprevention of HER-2/neu Transgenic Mammary Carcinoma through an Interleukin 12- Engineered Allogeneic Cell Vaccine," Cancer Research 64(11):4001-4009, June 1, 2004	
		DEGRENDELE et al., "The Anti-HER2 Monoclonal Antibody Pertuzumab May Be Effective in Androgen-Independent Prostate Cancer," Clinical Prostate Cancer 2(3):143-145, December 2003	
	1	DENNY, "Prodrug strategies in cancer therapy," Eur. J. Med. Chem. 36(7-8):577-595, July-August 2001	
		DERMER, "Another Anniversary for the War on Cancer," Bio/Technology 12:320, 1994	
		DE VOS, "Human Growth Hormone and Extracellular Domain of Its Receptor: Crystal Structure of the Complex," Science 255(5042):306-312, January 17, 1992	
		DI FIORE et al., "erbB-2 is a Potent Oncogene When Overexpressed in NIH/3T3 Cells," Science 237:178-182, 1987	
		DILLMAN, "Antibodies as Cytotoxic Therapy," J. Clin. Oncol. 12(7):1497-1515, 1994	
T		DOHERTY et al., "An Alternative HER-2/neu Transcript of 8 kb Has an Extended 3UTR and Displays Increased Stability in SKOV-3 Ovarian Carcinoma Cells," Gynecologic Oncology 74(3):408-415, 1999	
		DOUGALL et al., "The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies," Oncogene 9:2109-2123, 1994	
V		EARP et al., "Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research," Breast Cancer Research and Treatment 35:115-132, 1995	

			_
Examiner Signature	/Anne Holleran/	Date 09/06/2008	1
Orginolard		Considered	_

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 809. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation under citation (Kind Codes or USPPTO Patent Documents at <u>www.usplo.co</u> or MPEP 901.04* Either Office and its seved the document, by the two-letter code (WIPPO Sindard ST.3. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1,97 and 1,98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary organized proportion individual case. Any comments on the amount of time you require to compete this form another supposed proportions for reducing this submitted proportion in the Chef Information Officer, U.S. Paperland and Trademank Officer, U.S. Paperland of Todamank Officer, U.S. Paperland and Trademank Officer, U.S. Paperland of Todamank Officer, U.S. Paperland Officer, U.S. Paperland Officer, U.S. Paperland Officer, U.S. Paperland Of SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB064 (08-03)

Approved for use imrugh 07/31/2006, 080 695-031

U.S. Palent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection formation unriess in creating a valid OMB control number.

Ε

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

17

(Use as many sheets as necessary) of

Substitute for form 1449/PTO

Shoot 1 8

Complete if Known		
opplication Number	09/506,079	
iling Date	February 16, 2000	
irst Named Inventor	Gail M. Clinton	
art Unit	1643	
xaminer Name	Anne L. Holleran	
the control of the control	10001 10	

	,	NON PATENT LITERATURE DOCUMENTS	
xaminer nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, calafag, etc.), date, page(s), volume-issue number(s), publisher, du	T²
/A.H./		EKSTRAND et al., "Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails," Proc. Natl. Acad. Sci. 89.4309-4313, May 1992	
		FILMUS et al., "Amplified, Overexpressed and Rearranged Epidermal Growth Factor Receptor Gene in A Human Astrocytoma Cell Line," Biochemical and Biophysical Research Communications 131(1):207-215, August 30, 1985	
		FILMUS et al., "MDA-468, A Human Breast Cancer Cell Line With A High Number Of Epidermal Growth Factor (EGF) Roceptors, Has An Amplified EGF Receptor Gene And is Growth Inhibited By EGF," Blochemical and Biophysical Res	
		FINDEIS et al., "Targeted delivery of DNA for gene therapy via receptors," Trends Biotechnol. 11(5):202-205, May 1993	
		FITZPATRICK et al., "Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4," FEBS Letters 431:102-106, 1998	
		FLICKINGER et al., "An alternatively processed mRNA from the avian c-erbB gene encodes a soluble, truncated form of the receptor that can block ligand-dependent transformation," Mol. Cell. Biol. 12:883-893, 1992	
		GARRETT et al., "Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor Alpha," Cell 110(6):763-773, September 20, 2002	
		GILBERT et al., "Targeted prodrug treatment of HER-2-positive breast tumor cells using trastuzumab and paditaxel linked by A-Z-CINN™ Linker," Journal of Experimental Therapeutics and Oncology 3(1):27-35, January-February 2003	
		GILLOGLY et al., "Il-Key/HER-2/neu MHC class-Il antigenic epitope vaccine peptide for breast cancer," Cancer Immunol. Immunother. 53(6):490-496, June 2004	
		GIRNITA et al., "Cyclolignans as Inhibitors of the Insulin-Like Growth Factor-I Receptor and Malignant Cell Growth," Cancer Research 64(1):236-242, January 1, 2004	
		GRANERUS et al., "Effects of Insulin-Like Growth Factor-Binding Protein 2 And An IGF-Type I Receptor-Blocking Antibody On Apoptosis in Human Teratocarcinoma Cells in Vitro," Cell Biology International 25(8):825-828, 2001	
		GREENSPAN et al., "Defining epitopes: It's not as easy as it seems," Nature Biotechn. 17:936-937, 1999	_
		GREENSPAN et al., "Idiotypes: structure and immunogenicity," FASEB J. 75:437-444, 1993	_
		GROENEN et al., "Structure-Function Relationships for the EGF/TGF-Alpha Family of Mitogens," Growth Factors 11:235-257, 1994	
		GRZMIL et al., "Blockade of the type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF binding protein-3, and supresses MMP-2 expression," J. Pathol. 202(1):50-59, January 2004.	
		GURA, "Systems for Identifying New Drugs Are Often Faulty," Science 278:1041-1042, 1997	
		HANSEN, "Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill," Journal of immunological Methos 119:203-210, 1989	
V		HELDIN et al., "Ligand-induced Dimerization of Growth Factor Receptors: Variations on the Theme," Cytokine Growth Factor Reviews 7(1):3-10, 1996	

Examiner Signature	/Anne Holleran/	Date	09/06/2008
Signature		Considered	

EXAMINER. Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Petent Documents at www.susion.gov or MPEP 901 of "Einer Officion had issed the document, by the Workslews code (WPPO Standard ST.3)." For Japanese patent documents, the indication of the year of the regin of the Emperor must precade the serial number of the plasmid columnent. Find obscurrent by Rev of document to Merch Oscilland ST.3 of 15 possible. "Applicant is to proceed the processing of the Communication of the plasmid ST.3 of the processing of the Communication of the Communic a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

49321-16

EXPRESS MAIL NOS. EM245 (5009TUS AND EXCESSIONAUS.

U.S. Plantet and T. Approved for use long to polytrapions. One polytrapion. One polytrapio

Substitute for form 1449/PTO	Complete if Known		
INFORMATION DISCLOSURE	Application Number	09/506,079	
	Filing Date	February 16, 2000	
STATEMENT BY APPLICANT	First Named Inventor	Gail M. Clinton	
(Use as many sheets as necessary)	Art Unit	1643	
	Evaminer Name	Anne I Holleran	

Attorney Docket Number

Sheet 9 of 17

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), tille of the article (when appropriate), tille of the item (book, magazine, journel, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, andfor country where published.	T²
7A.H./		HELLAWELL et al., "Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin- like growth factor receptor," BJU International 91(3):271-277, February 2003	
		HONGO et al., "Antitumor Effects of a Souble Insulin-Like Growth Factor I Receptor in Human Ovarian Cancer Cells: Advantage of Recombinant Protein Administration in Vivo," Cancer Research 63(22):7834-7839, November 15, 2003	
		HU et al., "In Vivo Identification of the Interaction Site of ErbB2 Extracellular Domain With its Autoinhibitor," Journal of Cellular Physiology 205:335-343, 2005	
		HU et al., "Sequestering ErbB2 in endoplasmic reticulum by its autoinhibitor from translocation to cell surface. An autoinhibition mechanism of ErbB2 expression," Biochemical and Biophysical Research Communications 342(1):19-27, 2006	
		HUA et al., "SKOV3 Ovarian Carcinoma Cells Have Functional Estrogen Receptor but are Growth-resistant to Estrogen and Antiestrogens," J. Steroid Biochem. Molec. Biol. 55(3/4):279-289, 1995	
		HUDZIAK et al., "Increased expression of the putative growth factor receptor p185/HER2 causes transformation and tumorigenesis of NIH 373 cells," Proc. Natl. Acad. Sci. 84(20):7159-7163, 1987	
		HURWITZ et al., "Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake," Proc. Natl. Acad. Sci. 92(8):3353-3357, 1995	
		HUSE et al., "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science 248(4935):1275-1281, 1989	
		HUSTON et al., "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single- chain Fv analogue produced in Escherichia coli," Proc. Natl. Acad. Sci. 85:5879-5883, 1988	
		HWANG et al., "Expression of Epidermal Growth Factor Receptors and C-ER88-2 Proteins in Human Astrocytic Tumors," Kaohsiung Journal of Medical Sciences, 13(7):417-424, 1997	
1		HYNES et al., "The biology of erbB-2/neu/HER-2 and its role in cancer," Biochimica et Biophysica Acta 1198:165-184, 1994	
		JACK/SON et al., "Blockade of Epidermal Growth Factor- or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 Has Divergent Downstream Signaling and Growth Effects," Cancer Research 64(7):2601- 2609, April 1, 2004	
	1	JACKSON-BOOTH et al., "Inhibition of the Biologic Response to Insulin-like Growth Factor I in MCF-7 Breast Cancer Cells by a New Monoclonal Anablody to the Insulin-like Growth Factor-I Receptor. The Importance of Receptor Down-regulation," Horn. Metals. Res. 35(11-23)850-356, November-Docember 2003	
		JAIN, "Barriers to Drug Delivery in Solid Tumors," Scientific American 271(1):58-65, 1994	
		JEROME et al., "Anti-Insulin-Like Growth Factor Strategies in Breast Cancer," Semin. Oncol. 31(1 Suppl 3):54-63, February 2004	
V		JHABVALA-ROMERO et al., "Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2," Oncogene 22:8178-8186, 2003	

Examiner /Anne Holleran/	Date Considered	09/06/2008
--------------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 809. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. Applicants unique scation designation number (optional). See Kinds Codes of USPTO Petent Documents at <u>www.sspio.org</u> or MPEP 901 of 2⁴ Either Office that issued the document, by the Novelater code (NPPO Standard ST 3). *For Japanese patent documents, the indication of the year of the region of the Emperor must precede the serial number of the patent document. *For displacement is proprieted symbols as indicated on the document of the Osturded ST. 10 if passible. *Application is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 (sinu by , ne USP+1 U ne process) an apprication. Commonmently is governed by 30 U.S.C. 122 and 37 CPH 1.14. This collection is estimated to false 2 mbours to complete, including galantine, preparing, and submitting the completed application from the USPPT. The will vary depending upon the individual case. Any comments on the amount of time you require to complete this found marker suggestions for reducing this burder. And the chief Information Officer, U.S. Patentl and Tackenset (fide. U.S. Department of Commoner, P.C. De. 1456, Nationalida, VA. 22213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SIRMA (08-00)

Approved for use bringsh 07/3/05/08 65-003/

Approved for use bringsh 07/3/05/08 65-003/

U.S. Paient and Taddersh' Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid for it contains.

INFORMATION DISCLOSURE	Ē
STATEMENT BY APPLICANT	•

17

(Use as many sheets as necessary) of

Substitute for form 1449/PTO

Shoot 1 10

Complete if Known			
Application Number	09/506,079		
Filing Date	February 16, 2000		
First Named Inventor	Gail M. Clinton		
Art Unit	1643		
Examiner Name	Anne L. Holleran		
Attorney Docket Number	49321-16		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), tille of the article (when appropriate), tille of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), bublisher, city and/or country where published.	T²
/A.H./		JIA et al., "Specific Tumoricidal Activity of a Secreted proapoptotic Protein Consisting of HER2 Antibody and Constitutively Active Caspase-3," Cancer Research 63(12):3257-3262, June 15, 2003	
	<u> </u>	JOLLY, "Viral vector systems for gene therapy." Cancer Gene Therapy 1(1):51-64, March 1994	
		JUSTMAN et al., "Herstatin, an Autoinhibitor of the Human epidermal Growth Factor Receptor 2 Tyrosine Kinase, Modulates Epidermal Growth Factor Signaling Pathways Resulting in Growth Arrest," J. Biol. Chem. 277(23):20618-	
		KAPLITT et al., "Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain," Nature Genetics 8(2):148-154, October 1994	
		KERN et al., "Inhibition of Human Lung Cancer Cell Line Growth by an Anti-p185(HER2) Antibody," American Journal of Respiratory Cell and Molecular Biology 9:448-454, 1993	
		KIMURA et al., "Retroviral Delivery of DNA into the Livers of Transgenic Mice Bearing Premalignant and Malignant Hepatocellular Carcinomas," Human Gene Therapy 5(7):845-852, July 1994	
		KIRSCH et al., 'BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II," The EMBO Journal 19(13):3314-3324, 2000	
		KÖHLER et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature 256:495-497, 1975	
		KOZBOR et al., "The production of monoclonal antibodies from human lymphocytes," Immunology Today 4(3):72-79, 1983	
		KRAINER et al., "Tissue Expression and Serum Levels of HER-2/neu in Patients with Breast Cancer," Oncology 54:475-481, 1997	
		KRAUS et al., "Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms," EMBO J. 6:605-610, 1987	
		KUMAGAI et al., "The role of distinct p185(neu) extracellular subdomains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling," Proc. Natl. Acad. Sci. 98(10):5526-5531, 2001	
		KUROKAWA, "Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells," Cancer Res. 60:5887-5894, 2000	
		LANGTON et al., "An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-ERBB-2 (Her-2/Neu) oncogene," Canc. Res. 51:2593-2598, 1991	
		LAX et al., "Localization of a Major Receptor-Binding Domain for Epidermal Growth Factor by Affinity Labelling," Molecular and Cellular Biology 8(4):1831-1834, 1988	
		LEE et al., "Isolation and characterization of four alternate c-erbB3 transcripts expressed in ovarian carcinoma-derived cell lines and normal human tissues," Oncogene 18:3243-3252, 1998	
V		LEE et al., "A Naturally Occurring Secreted Human ErbB3 Receptor Isoform Inhibits Heregulin-stimulated Activation of ErbB2, ErbB3, and ErbB4," Cancer Research 61:4467-4473, 2001	

Examiner	/Anne Holleran/	Date	09/06/2008
Signature	77 WHITE TRONGRAFIE	Considered	

EXAMINER: Initial if reference considered, whether or not clatton is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation unimber (optional). See Kinds Codes of USPTO Petent Documents at www.uspic.org or MPEP 9010 of "Enter Office that issued the document," by the Noveletze code (MPPO Standard ST.3). For Japanese patent documents, the indication of the year of the region of the Emperor must precede the serial number of the patent of t a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file This commontant environment is required by 2 of Ver. 1 of affin 1 bit of mention with 1 common and 2 of the 1 SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SBIRSA (08-03)

Approved for use through 07/31008 MB 953-1003

U.S. Patent and Trademark Office; U.S. IDPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of informetion unless (contains a valid of control number.

Substi	tute for form 1449/PTC)		Co	mplete if Known	
INF	ORMATIO	N D	SCLOSURE	Application Number	09/506,079	
				Filing Date	February 16, 2000	
ST	ATEMENT	BY A	APPLICANT	First Named Inventor	Gail M. Clinton	
	(Use as many sh	eets as	necessary)	Art Unit	1643	
				Examiner Name	Anne L. Holleran	
·	11		47	Attornou Dooket Number	40221 18	

Examiner	Cite	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	T²
nitials*	No.1	number(s), publisher, city and/or country where published.	
/A.H./		LEE at al., "Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer," Cancer Gene Therapy 10(1):57-63, January 2003	
		LEE et al., *Requirement for neuregulin receptor erbB2 in neural and cardiac development,* Nature 378:394-398, 1995	
		LEE et al., "Serum Tyrosine Kinase Activity and Neoplastic Disease," Recent Results in Cancer Research 113:32-40, 1989	
		LEITZEL et al., "Elevated Soluble c-erbB-2 Antigen Levels in the Serum and Effusions of a Proportion of Breast Cancer Patients," Journal of Clinical Oncology 10(9):1436-1443, 1992	
Π		LEMMON et al., "Two EGF molecules contribute additively to stabilization of the EGFR dimer," The EMBO Journal 16(2):281-294, 1997	
		LEWIS et al., "Differential responses of human tumor cell lines to anti-p185(HER2) monoclonal antibodies," Cancer Immunology Immunotherapy 37:255-263, 1993	
		LI et al., "Cytotoxicity of human prostate cancer cell lines in vitro and inductin of apoptosis using ²¹³ Bi-Herceptin alpha- conjugate," Cancer Letters 205(2):161-171, March 18, 2004	
		LIBERMANN et al., "Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin," Nature 313: 144-147, 1985	
		LIN et al., "Characterization of tyrosyl kinase activity in human serum," J. Biol. Chem. 260(3) 1532-1587, 1985	
-		LIN et al., "Developmental Expression of Tyrosyl Kinase Activity in Human Serum," Human Biology 59(3):549-556, 1987	
Т		LIN et al., "Disulfide-Linked and Noncovalent Dimers of p185(HER-2) in Human Breast Carcinoma Cells," Journal of Cellular Biochemistry 49(3):290-295, 1992	
		LIN et al., "The Epidermal Growth Factor Receptor from Prostate Cells Is Dephosphorylated by a Prostate-Specific Phosphotyrosyl Phosphatase," Mol. Cell Biol. 8(12): 5477-5485, December 1988	
		LIN et al., "Human prostatic acid phosphatase has phosphotyrosyl protein phosphatase activity," Biochem. J. 235:351-357, 1986	
Т		LIN et al., "Insulin and epidermal growth factor stimulate phosphorylation of p185(HER-2) in the breast carcinoma cell line, BT474," Molecular and Cellular Endocrinology 69(2-3):111-119, 1990	
		LIN et al., "A soluble protein related to the HER-2 proto-oncogene product is released from human breast cardinoma cells," Oncogene 6(4):639-643, 1991	
		LIN et al., "Tyrosyl Kinase Activity is Inversely Related to Prostatic Acid Phosphatase Activity in Two Human Prostate Carcinoma Cell Lines," Mol. Cell Biol. 6(12):4753-4757, December 1986	
\overline{V}		LIU et al., "MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo," Breast Cancer Res. Treatment 34 97-117, 1995.	

Examiner	/Anne Holleran/	Date	09/06/2008
Signature		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through clusters if the incomplement of considered include copy of this form with next communication applicant. Applicant's unique clusters designed the manner (regional), "See a formation of the property of

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 loss of the finding galanteen pearing, and submitting the completed application from the USPT. Time will vary department of use to complete, including galanteen pearing, and submitting the completed application from the USPT. Time will vary department of use to complete the policitation from the USPT. Time will vary department of including case. Any comment of the policitation from the USPT. Time will vary department of under the USPT. Time will vary department of un SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

49321-16

Attorney Docket Number

Substitute for form 1449/PTO	C	ompiete if Known	
INFORMATION DISCLOSURE	Application Number	09/506,079	Ξ
	Filing Date	February 16, 2000	Ξ
STATEMENT BY APPLICANT	First Named Inventor	Gail M. Clinton	
(Use as many sheets as necessary)	Art Unit	1643	Ξ
	Examiner Name	Anne L. Holleran	

Sheet 12 of 17

		NON PATENT LITERATURE DOCUMENTS	
xaminer nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages), volume-issue number(s), publisher, oily andro country where published.	T2
/A.H./		LU et al., "Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor-Negative Mammary Tumors," Journal of the National Cancer Institute 95(24):1825-1833, December 17, 2003	
		LU et al., "Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)," Journal of the National Cancer Institute 93(24):1852-1857, December 19, 2001	
		LU et al., "Molecular Mechanisms Underlying IGF-I-Induced Attenuation Of The Growth-Inhibitory Activity of Trastuzumab (Herceptin) On SKBR3 Breast Cancer Cells," Int. J. Cancer 108(3):334-341, January 20, 2004	
		LU et al., "Simultaneous Blockade of Both the Epidemal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody," The Journal of Biological Chemistry 279(4):265-2685, January 23, 2004	
		MAISONPIERRE et al., "Angiopoletin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis," Science 277(5322):55-60, 1997	
		MALONEY, "An Anti-Insulin-like Growth Factor I Receptor Antibody That Is a Potent Inhibitor of Cancer Cell Proliferation," Cancer Research 63(16):5073-5083, August 15, 2003	
		MEDEN et al., "Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy," J. Canc. Res. Clin. Oncol. 120:378-381, 1994	
		MEDEN et al., "Prognostic Significance of p105 (c-erb8-2, HER2/neu) Serum Levels in Patients with Ovarian Cancer," Anticancer Research 17:757-760, 1997	
		MILLER et al., "Regulation of HER2/neu gene expression (Review)," Oncology Reports 2:497-503, 1995	
		MIN et al., "Senetic Blockade of the Insulin-like Growth Factor-I Receptor: A Promising Strategy for Human Pancreatic Cancer," Cancer Research 63(19):6432-6441, October 1, 2003	
		MTSIADES et al., "Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors," Cancer Cell 5(3):221-230, March 2004	
		MOLINA et al., "NH-terminal Truncated HER-2 Protein but not Full-Length Receptor is Associated with Nodal Metastasis in Human Breast Cancer," Clinical Cancer Research 8:347-353, 2002	
		MORRISON et al., "Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains," Proc. Natl. Acad. Sci. 81:8851-6855, 1984	
		MOSCATELLO et al., "Transformation and altered signal transduction by a naturally occurring mutant EGF receptor," Oncogene 13:85-96, 1996	
		MYERS et al., "Elevated Serum Levels of p105(erb8-2) in Patients with Advanced-Stage Prostatic Adenocarcinoma," Int. J. Cancer (Pred. Oncol.) 69:398-402, 1996	
		NAHTA et al., "The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells," Cancer Research 64(7):2343-2348, April 1, 2004	
$\overline{\Psi}$		NAIDU et al., "Antiproliferative and apoptotic effect of ascorbyl stearate in human glioblastoma multiforme cells: modulation of insulin-like growth factor-I receptor (IGF-IR) expression," Journal of Neuro-Oncology 54(1):15-22, August 2001	

Examiner	/Anne Holleran/	Date	09/06/2008
Signature		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation despination number (optional). See Kinds Codes of USPFP 9101. Deep 100 permits at www.suppo.cop or MPEP 9101.0° Either Office that issued the document. by the two-letter code (MPPC Standard ST 3). For Japanese patent documents at which of the patent of the patent of the patent of the communication of the communication of the patent of the a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB076A (08-02)

Approved for use through 07/31/2006, 088 8053-4031

U.S. Palent and Trademic Office; U.S. EDPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless in contains a valid OMB control number.

Substitute for form 1449/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

of 17

Complete if Known
Application Number 09/505,079
Filling Date February 16, 2000
First Named Inventor Gail M. Clinton
Art Unit 1643
Examiner Name Anne L. Holleran

49321-16

(Use as many sheets as necessary)

Sheet 13

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sorial, symposium, catalog, etc.), date, page(s), volume-issue unwber(s), publisher, city and/or contry where publisher.	T²
/A.H./		NATALI et al., "Expression of the p185 Encoded by HER2 Oncogene in Normal and Transformed Human Tissues," Int. J. Cancer 45:457-461, 1990	
		NEUBERGER et al., "Recombinant antibodies possessing novel effector functions," Nature 312:604-608, 1984	
		NEUWELT et al., "Inhibition of brain tumor growth by Herstatin, an autoinhibitor of the EGF receptor family," Proceedings of the American Association for Cancer Research Annual Meeting, 44 1232, 2003 (abstract only)	
		NISHIKAWA et al., "A mutant epidermal growth factor receptor common in human giloma confers enhanced tumorigenicity," Proc. Natl. Acad. Sci. 91:7727-7731, August 1994	
		NISONOFF, "Idiotypes: Concepts and Applications," Journal of Immunology 147(8):2429-2438, 1991	
		OBRENOVICH et al., "Overexpression of GRK2 in Alzheimer Disease and in a Chronic Hypoperfusion Rat Model is an Early Marker of Brain Mitochondrial Lesions," Neurotoxicity Research 10(1):43-56, 2006	
		OLAYIOYE et al., "The ErbB signaling network: receptor heterodimerization in development and cancer," EMBO Journal 19(13):3159-3167, July 3, 2000	
		O'ROURKE et al., "Trans receptor inhibition of human glioblastoma cells by erbB family ectodomains," Proc. Natl. Acad. Sci. 94(7):3250-3255, 1997	,
		PAVELIC et al., "Evidence for a Role of EGF Receptor in the Progression of Human Lung Carcinoma," Anticancer Research 13:1133-1138, 1993	
		PEGRAM et al., "Biological Rationale for HER2/neu (c-erb82) as a Target for Monoclonal Antibody Therapy," Seminars in Oncology 27(5)(Suppl. 9):13-19, 2000	
		PETCH et al., "A fruncated, secreted form of the epidermal growth factor receptor is encoded by an alternatively spliced transcript in normal rat tissue," Mol. Cell. Biol. 10:2973-2982, 1990	
		PHILLIP et al., 'Efficient and Sustained Gene Expression in Primary T Lymphocytes and Primary and cultured Tumor Cells Mediated by Adeno-Associated Virus Plasmid DNA Complexed to Cationic Liposomes,' Molecular and Cellular Biology 16(4):2411-2418, pdf 1994	
		PIETRAS et al., "HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells," Oncogene 10:2435-2446, 1995	
		PINCKARD et al., "Factors Influencing The Immune Response. I. Effects Of The Physical State Of The Antigen And Of Lymphoreticular Cell Profiferation On The Response To Intravenous Injection Of Bovine Serum Albumin In Rabbits," Clin. Exp. Immunol. 2(3):331-341, May 1987	
		PUPA et al., "The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage," Oncogene 8:2917-2923, 1993	
		QIAN et al., "Intermolecular Association and Trans-phosphorylation of Different neu-Kinase Forms Permit SH2- dependent Signaling and Oncogenic Transformation," Oncogene 10:211-219, 1995	
\overline{V}		REINMUTH et al., "Blockade of Insulin-like Growth Factor I Receptor Function Inhibits Growth and Angiogenesis of Colon Cancer," Clinical Cancer Research 8(10):3259-3269, October 2002	

Attorney Docket Number

Examiner Signature	/Anne Holleran/	Date Considered	09/06/2008
		Considered	

EXAMINE: Initial if reference considered, whether or not cisation is in conformation with MPEP 609. Draw line through claston in not in conformation and not considered. Include copy of this form with nex communication to applicant. * Applicants* in unique citation designation number (opinions). * See Kinds Codes of USPTO Pasent Documents at www.uspito.gov or MPEP 901.04 * Enter Office that issued the document, by the Novel the code (WPE) of the code of USPTO Pasent Documents at www.uspito.gov or MPEP 901.04 * Enter Office that issued the document, by the Novel the code (WPE) Standard ST3. * For Japanese patient document, by the opinication of the year of the reigh of the Emporer must precede the serial number of the patient document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. * Applicant is to place a check mark here if English inauques per Translation is attacked.

a crack miss held in England in Webper and 19.8 The Information is required to obtain or retain a benefit by the public which is to file in Complete the Complete displayable the Complete Complete Complete the Complete the Complete Complete the Complete C

Exercised min. Thus, Etter-21 Joseph (11/5 AND EMERS) 513-5005.

U. S. Pieser I Tradermik Office U. S. DEPARTMENT OF COMMENCE.

U. S. Pieser I Tradermik Office U. S. DEPARTMENT OF COMMENCE.

Under the Propervork Reduction Act of 1956, no persons are required to respond to a collection of information unless a constains a wide office constainment.

Subs	titute for form 1449	/PTO		Co	mplete if Known	
IN	FORMAT	ION DI	SCLOSURE	Application Number	09/506,079	
	. •			Filing Date	February 16, 2000	
ST	ATEMEN	IT BY A	APPLICANT	First Named Inventor	Gail M. Clinton	
	(Use as mar	y sheets as	necessary)	Art Unit	1643	
	•			Examiner Name	Anne L. Holleran	
Sheet	14	of	17	Attorney Docket Number	49321-16	

xaminer	Cite No. '	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, clip and/or country where published.	T²
A.H./		ROBBINS et al., "Antibodies to Covalent Aggregates of Insulin in Blood on Insulin-Using Diabetic Patients," Diabetes 36:338-841, July 1987	
		RUDIKOFF et al., "Single amino acid substitution attering antigen-binding specificity," Proc. Natl. Acad. Sci. 79:1979-1983, 1982	
		SACHDEV et al., "A Chimeric Humanized Single-Chain Antibody against the Type I Insulin-like Growth Factor (IGF) Receptor Renders Breast Cancer Cells Refractory to the Mitogenic Effects of IGF-I," Cancer Research 83(8) 627-635, February 1, 2003	
		SALATINO et at., "Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity, "Oncogene 23(30):518-1374, July 1, 2004	
		SALISBURY et al., "Development of Molecular Agents for IGF Receptor Targeting," Horm. Metab. Res. 35(11-12):843-849, November-December 2003	
		SAMANI et al., "Inhibition of Carcinoma Cell Growth and Metastasis by a Vesicular Stomattis Virus G-Pseudotyped Retrovector Expressing Type I Insulin-Like Growth Factor Receptor Antisense," Human Gene Therapy 12(16):1989- 1977. November 1, 2001	
		SAMINI et al., "Loss of Tumorigenicity and Metastatic Potential in Carcinoma Cells Expressing the Extracellular Domain of the Type 1 Insulin-Like Growth Factor Receptor," Cancer Research 64(10):3380-3385, May 15, 2004	
		SCHALLER et al., "Therapy of metastatic breast cancer with humanized antibodies against the HER2 receptor protein," J. Cancer Res. Clin. Oncol. 125:520-524, 1999	
		SCHWEITZER et al., "Inhibition of Drosophila EGF receptor activation by the secreted protein Argos," Nature 376:699-702, 1995	
		SCOTLANDI et al., "Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells," Cancer Gene Therapy 9(3):296-307, March 2002	
		SCOTLANDI et al., "Expression Of An IGF-I Receptor Dominant Negative Mutant Induces Apoptosis, Inhibits Tumorigenesis And Enhances Chemosensitivity in Ewing's Sarcoma Cells," Int. J. Cancer 101(1):11-16, September 1, 2002	
		SEARCH REPORT: Supplementary Partial European Search Report, Application Number EP 00930067, 7/8/02, 3 pages	
		SEGATTO et al., "Different Structural Alterations Upregulate In Vitro Tyrosine Kinase Activity and Transforming Potency of the erb8-2 Gene," Mol. Cell. Biol. 8(12):5570-5574, 1988	
		SEQUENCE SEARCH RESULTS, Issued Patents database, "us-10-204-102a-1.rai", p. 1-2	
		SEVERINO et al., "Rapid loss of oestrogen and progesterone receptors in human leiomyoma and myometrial explant cultures," Mol. Human Repro. 2(11):823-828, 1996	
$\overline{\mathbf{V}}$		SHAMIEH et al., "The intron 8-encoded domain of Herstatin encodes a receptor binding module that is required for erbB receptor inhibition," Proceedings on the American Association for Cancer Research 44:1233, 2003 (abstract only)	

			_
Examiner	/Anne Holleran/	Date 09/06/2008	1
Signature		Considered	ш

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 800. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. Applicants unique closellation designation number (postions). See Kinds Codes or LISPEP 0 Feath Documents at www.sagio.gov or MPEP 801 out "Enter Office that issued the document, by the two-letter code (MPD Standard S1.3)." For Japanese patent documents, the indication of the year of the region of the Emperor must precede the sentin number of the patent document. Yet of document by the appropriate symbols as indicated on the Countem under VMP Standard S1.1 or passible. "Application is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the nours to complete, including gathering, preparing, aird southing the complete supplementation in the Corrol will vary object and individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DONOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/10/200. MIR O'SMIR (1994)

U.S. Palent and Trademark Office; U.S. EPERANTE O'SMIR (1994)

U.S. Palent and Trademark Office; U.S. EPERANTE O'S O'SMIR (1994)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a cellection of information urface its choralism as without number. Α

> F Α

> > E

INFORMATION DISCLOSURE	
STATEMENT BY APPLICANT	

17

(Use as many sheets as necessary) of

Substitute for form 1449/PTO

Shoot 15

Complete if Known		
pplication Number 09/506,079		
iling Date	February 16, 2000	
irst Named Inventor	Gail M. Clinton	
rt Unit	1643	
xaminer Name	Anne L. Holleran	
ttomey Docket Number	49321-16	

		NON PATENT LITERATURE DOCUMENTS	
xaminer nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), votume-issue number(s), politisher, day andro country where published.	T²
/A.H./		SHARP et al., "Classification of introns: U2-type or U12-type," Cell 91:875-879, 1997	
		SHEPARD et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic," J. Clin. Immunol. 11(3):117-127, 1991	
		SLAMON et al., "The Future of ErbB-1 and ErbB-2 Pathway Inhibition in Breast Cancer: Targeting Multiple Receptors," Oncologist g(Suppl 3):1-3, 2004	
		SLAMON et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene," Science 235(4785):177-182, 1987	
		SLAMON et al., "Studies of the HER-2/neu Proto-Oncogene in Human Breast and Ovarian Cancer," Science 244(4905):707-712, 1989	
		SMITH, "Comparison of Biosequences," Advances in Applied Mathematics 2:482-489, 1981	
		SMITH et al., "Human Interleukin 4: The Solution Structure of a Four-helix Bundle Protein," J. Mol. Biol. 244:899-904, 1992	
		STANCOVSKI et al., "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth, "Proc. Natl. Acad. Sci. 88:8691-8695, 1991	
		STAVEROSKY et al., "Herstatin, an autoinhibitor of the epidermal growth factor (EGF) receptor family, blocks the intracranial growth of glioblastoma," Clin. Cancer Res. 11(1):335-340, 2005	
		STEBBING et al., "Herceptin (trastuzamab) in advanced breast cancer," Cancer Treatment Reviews 26(4):287-290, August 2000	
		Stedman's Medical Dictionary 27th Edition, Lippicott Williams & Wilkins, 2000, definition for astrocyte	
		Stedman's Medical Dictionary 27th Edition, Lippicott Williams & Wilkins, 2000, definition for glial	
		STEIN et al., "Evolutionary Analysis of the ErbB Receptor and Ligand Families," J. Mol. Evol. 50(5):397-412, May 2000	
		STERN et al., "p185, a product of the neu proto-oncogene, is a receptor like protein associated with tyrosine kinase activity," Mol. Cell. Biol 6:1729-1740, 1986	
		ST.JACQUES et al., "Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-beta binding protein of endothelial and stromal cells," Endocrinology 134:2645-2657, 1994	
		STROBEL et al., "Beta-1 Integrins Parily Mediate Blinding of Ovarian Cancer Cells to Peritoneal Mesothelium in Vitro," Gynecologic Oncology 73:362-367, 1999	
		SURMACZ, "Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor," Oncogene 22(42):6589-6597, September 29, 2003	
		TAKEDA et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," Nature 314:452-454, 1985	
V		TAL et al., "Human HER2 (neu) promoter: evidence for multiple mechanisms for transcriptional initiation, Mol. Cell. Biol. 7(7):2597-2601, 1987	

Examiner	/Anne Holleran/	Date	09/06/2008
Signature		Considered	

EXAMINE. Initial in feterors considered, whether or not claims in in conformation with NPEP 900. Dawy line through claims in fine in conformation and not considered models only of the form with these communication to supplement. Application in unique catalon claimpained number opportunit. See Noted Codes of USPTO Patent Documents at www.usofa.gov or MPEP 901.04.* Enter Office that issued the document, by the volument occurrent. See Noted Codes of USPTO Patent Documents at www.usofa.gov or MPEP 901.04.* Enter Office that issued the document, by the volument occurrent. For example, the proper must precede the serial number of the patent document. Kind of document under WIPO Standard ST3. If if possible. *Applicant is to place a check mark here I English Integrage Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it contains a valid OMB control number. Under the Panerwork Reduction Act of 1995, no persons are required to res

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449/PTO

Shoot 16

(Use as many sheets as necessary) of

17

Complete if Known		
Application Number 09/506,079		
Filing Date	February 16, 2000	
First Named Inventor	Gail M. Clinton	
Art Unit	1643	
Examiner Name	Anne L. Holleran	
Attorney Docket Number	49321-16	

xaminer	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), butlisher, city, and/or country where published.	T ²
/A.H./	No. '	TANNER et al., "Dimerization of the Estracellular Domain of the Receptor for Epidemal Growth Factor Containing the Membrane-spanning Segment in Response to Treatment with Epidermal Growth Factor," Journal of Biological	
		TOPP et al., "Antibody transport in cultured tumor cell layers," Journal of Controlled Release 53:15-23, 1998	
		TYSON et al., "Expression and amplification of the HER-2/neu (c-erb8-2) protooncogene in epithelial ovarian tumors and cell lines," Am. J. Obstet. Gynecol. 165(3):640-646, 1991	
T		TZAHAR et al., "Bivalence of EGF-like ligands drives the ErbB signaling network," EMBO Journal 16(16):4938-4950, 1997	
		TZAHAR et al., "The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligants," Blochimica et Biophysica Acta 1377(1):M25-M37, February 20, 1998	
		ULLRICH et al., "Human epidermal growth factor receptor cDNA sequence and abermant expression of the amplified gene in A431 epidermoid carcinoma cells," Nature 309:418-425, 1984	
		VALERON et al., "Validation of a differential PCR and an ELISA procedure in studying HER-2/neu status in breast cancer," Int. J. Cancer 65:129-133, 1996	
		VAN OSTADE et al., "Human TNF mutants with selective activity on the p55 receptor," Nature 361(6409):266-269, January 21, 1993	
		VECCHI et al., "Constitutive proteolysis of the ErbB-4 receptor tyrosine kinase by a unique, sequential mechanism," J. Cell. Biol. 139:995-1003, 1997	
		VECCHI et al., "Selective cleavage of the heregulin receptor ErbB-4 by protein kinase C activation," J. Biol. Chem. 271:18989-18995, 1996	
		WANG et al., "Insulin-Like Growth Factor Receptor-1 as an Anti-Cancer Target: Blocking Transformation and Inducing Apoptosis," Current Cancer Drug Targets 2:191-207, 2002	
		WARD et al., "Binding activities of a repertoire of single immunogobulin variable domains secreted from Escherichia coli," Nature 341:544-546, 1989	
		WINER et al., "New Combinations with Herceptin® in Metastatic Breast Cancer," Oncology 61 (Supplement 2):50-57, 2001	
		WOFFENDIN et al., "Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells," Proc. Natl. Acad. Sci. 91(24):11581-11585, November 22, 1994	
		WOLT JER et al., "Direct identification of residues of the epidermal growth factor receptor in close proximity to the amino terminus of bound epidermal growth factor," Proc. Natl. Acad. Sci. 89(16):7801-7805, 1992	
		WU et al., "Human epidermal growth factor receptor residue covalently cross-linked to epidermal growth factor," Proc. Natl. Acad. Sci. 87:3151-3155, 1990	
$\overline{\mathbb{V}}$		WU et al., "Incorporation of Adenovirus into a Ligand-based DNA Carrier System Results in Retention of Original Receptor Specificity and Enhances Targeted Gene Expression," The Journal of Biological Chemistry 269(15):11542-11548, April 15, 1994	

09/06/2008 Examiner Date /Anne Holleran/ Signature

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Coder of USPTO Patent Documents at https://www.usto.gov/or nMPEP-901.04 "There Office that issued the document, by the two-letter must precede the serial number of the patent and S13.1" For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent. document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 unu uy ne uur 1 uu prucess) ari appirization. Commontaniiny is governed by 30 U.S.C. 122 and 3 /C Uhr. 1.14. This collection is eliminate four flowers to complete, including gathening preparing, and submilling the completed application from the tUSPTO. The well vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this butter is hough the submilling that the competence of SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/Subra (06.30)
Approved for use through 07/13/08/08/51-0031
U.S. Pelent an Trademix Office; U.S. CEPARTINENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless to notating a valid octer for number.

INFORMATION	DISCLOSURE
STATEMENT B	Y APPLICANT

Substitute for form 1449/PTO

Sheet 17

(Use as many sheets as necessary) of

17

Complete if Known			
Application Number 09/506,079			
Filing Date	February 16, 2000		
First Named Inventor	Gail M. Clinton		
Art Unit	1643		
Examiner Name	Anne L. Holleran		
Attorney Docket Number	49321-16		

		NON PATENT LITERATURE DOCUMENTS		
xaminer nitials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serid, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T²	
/A.H./		WU et al., "Receptor-mediated Gene Delivery and Expression in Vivo," The Journal of Biological Chemistry 263(29):14621-14624, October 15, 1988		
		WU et al., "Receptor-mediated Gene Delivery in Vivo: Partial Correction of Genetic Analbuminemia in Nagase Rats," The Journal of Biological Chemistry 266(22):14338-14342, August 5, 1991	1	
		WU et al., "Targeting Genes: Delivery and Persistent Expression of a Foreign Gene Driven by Mammalian Regulatory Elements in Vivo," The Journal of Biological Chemistry 264(29):16985-16987, October 15, 1989		
		XIA et al., "Combination of EGFR, HER-2/neu, and HER-3 is a Stronger Predictor for the Outcome of Oral Squamous Cell Carcinoma than any Individual Family Members," Clin. Cancer Res. 5:4164-4174, 1999		
		XU et al., "Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-eroB-2 (HER-2/neu) gene product p185," Int. J. Canc. 53:401-408, 1993		
		XU et al., "Heregulin and agonistic anti-p185(c-erb82) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erb82): increased invasiveness may contribute to poor prognosis," Clinical Cancer Research 3(9):182-1844, 1997		
		XU et al., "Strategies for Enzyme/Prodrug Cancer Therapy," Clinical Cancer Research 7(11):3314-3324, November 2001		
		YARDEN et al., "Untangling the ErbB Signalling Network," Nature Reviews Molecular Cell Biology 2(2):127-137, February 2001		
		YE et al., "Combined Effects of Tamoxifen and a Chimeric Humanized Single Chain Antibody against the Type I IGF Receptor on Breast Tumor Growth In Vivo," Horm. Metab. Res. 35(11-12):836-842, November-December 2003		
		ZENKE et al., "Receptor-mediated endocytosis of transferin-polycation conjugates: An efficient way to introduced DNA into hematopoietic cells," Proc. Natl. Acad. Sci. 87(10):3655-3659, May 1990		
		ZHOU et al., "Effects Of The EGFR/HER2 Kinase Inhibitor GW572016 On EGFR- And HER2-Overexpressing Breast Cancer Cell Line Proliferation, Radiosensitization, And Resistance," Int. J. Radiation Oncology Biol. Phys. 58(2):344-352, February 1, 2004		
W_		ZIPS et al., "New Anticancer Agents: In Vitro and In Vivo Evaluation," In Vivo 19:1-7., 2005		
	-			
	1			
	\vdash			
	+-			
	+			

Examiner	/Anne Holleran/	Date	09/06/2008
Signature	77 ITTIO TIONOFATE	Considered	<u> </u>

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of LISPTO Pleatin Documents all <u>www.sichory.co</u> or MPEP 901.01 of "enter Office that issued the documents, by the Not-elter code (MPIPC Standard ST.3)." For Japanese patent documents, the indication of the year of the regin of the Emperor must precede the social number of the plant of comments by the appropriate symbols as indicated on the Cooument unifor MPC Standard ST. 1 if pessible. "Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.